الفهرس | Only 14 pages are availabe for public view |
Abstract Acute leukemia is a cancer of the early blood-forming cells that affects the blood and bone marrow and can be divided in two main classes; acute myeloid leukemia (AML) and acute lymphocytic Leukemia (ALL). The accumulation of these malignant clones dominates on the normal bone marrow activity and leads to marrow failure. In AML, the survival and proliferation of hematopoietic progenitor cells are enhanced by both deregulation of many signaling pathways and abnormalities occur in the transcription factors functions Angiogenesis is one of the factors is involved in the process of cancer progression and metastasis. Angiogenesis is a sequence of different processes that start with the diltation in pre-existing vessels then proliferation of endothelial cells, development of new blood vessels and recruitment of the perivascular cells (PCs). Therefore, angiogenesis is a key factor in tumor progression and metastasis. Vascular endothelial growth factor (VEGF) is one of the growth factors well known for controlling the angiogenesis process. Vascular endothelial growth factors (VEGF) are a group of angiogenesis-promoting proteins has a role in primary tumor growth, invasion and metastasis associated with many cancer types like breast, lung, renal and prostate cancers as well as leukemia .VEGF is highly polymorphic gene, and its promoter, 5’- and the 3’-untranslated region (UTR) has a variety of Single nucleotide polymorphisms (SNPs) which found to be associated with variations in VEGF protein production. VEGF 699947 SNP is found in Peripheral Blood Mononuclear Cells of Iranian, Australian, Caucasian and African patients with acute myeloid leukemia. |